ArticleCancer science2017
Establishment of a dog primary prostate cancer organoid using the urine cancer stem cells.
Article in Cancer science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- A systematic review on the culture methods and applications of 3D tumoroids for cancer research and personalized medicine.Cellular oncology (Dordrecht, Netherlands) · 2025Pooled it
- Recent Advances in Graphene Oxide-Based on Organoid Culture as Disease Model and Cell Behavior - A Systematic Literature Review.International journal of nanomedicine · 2024Pooled it
- Animal organoids as models for integrated One Health research.One health (Amsterdam, Netherlands) · 2026Review
- Innovative In Vitro-In Silico Platform for Dose-Response Modeling in Canine Bladder Cancer: A 3D Organoid- and Mathematics-Based Approach.The AAPS journal · 2026Article
- Bladder organoid conditioned media enhances myoblast proliferation under serum free conditions.Scientific reports · 2026Article
- Perspective: from pathogenesis to treatment in veterinary science through organoid disease modelling.Frontiers in veterinary science · 2026Article
- Establishment of an experimental model of canine apocrine gland anal sac adenocarcinoma organoid culture using a three-dimensional culture method.Scientific reports · 2025Article
- A microfluidics platform for simultaneous evaluation of sensitivity and side effects of anti-cancer drugs using a three-dimensional culture method.Scientific reports · 2025Article
- Canine organoids: state-of-the-art, translation potential for human medicine and plea for standardization.Frontiers in veterinary science · 2025Review
- Establishment and transcriptomic characterization of canine organoids from multiple tissues.Frontiers in cell and developmental biology · 2025Article
- Usability of serum hedgehog signalling proteins as biomarkers in canine mammary carcinomas.BMC veterinary research · 2023Article
- Article
- Establishment and characterization of canine mammary tumoroids for translational research.BMC biology · 2023Article
- Current status and clinical application of patient-derived tumor organoid model in kidney and prostate cancers.BMB reports · 2023Review
- Advances in organoid technology for veterinary disease modeling.Frontiers in veterinary science · 2023Review
- Companion animal organoid technology to advance veterinary regenerative medicine.Frontiers in veterinary science · 2023Review
- A living biobank of canine mammary tumor organoids as a comparative model for human breast cancer.Scientific reports · 2022Article
- The World of Organoids: Gastrointestinal Disease Modelling in the Age of 3R and One Health with Specific Relevance to Dogs and Cats.Animals : an open access journal from MDPI · 2022Review
- Urological cancer organoids, patients' avatars for precision medicine: past, present and future.Cell & bioscience · 2022Review
- Farm and Companion Animal Organoid Models in Translational Research: A Powerful Tool to Bridge the Gap Between Mice and Humans.Frontiers in medical technology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dog spontaneously develop prostate cancer (PC) like humans. Because most dogs with PC have a poor prognosis, they could be used as a translational model for advanced PC in humans. Stem cell-derived 3-D organoid culture could recapitulate organ structures and physiology. Using patient tissues, a human PC organoid culture system was established. Recent study has shown that urine cells also possess the characteristic of stem cells. However, urine cell-derived PC organoids have never been produced. Therefore, we generated PC organoids using the dog urine samples. Urine organoids were successfully generated from each dog with PC. Each organoid showed cystic structures and resembled the epithelial structures of original tissues. Expression of an epithelial cell marker, E-cadherin, and a myofibloblast marker, α-SMA, was observed in the urine organoids. The organoids also expressed a basal cell marker, CK5, and a luminal cell marker, CK8. CD49f-sorted basal cell organoids rapidly grew compared with CD24-sorted luminal cell organoids. The population of CD44-positive cells was the highest in both organoids and the original urine cells. Tumors were successfully formed with the injection of the organoids into immunodeficient mice. Treatment with a microtubule inhibitor, docetaxel, but not a cyclooxygenase inhibitor, piroxicam, and an mTOR inhibitor, rapamycin, decreased the cell viability of organoids. Treatment with a Hedgehog signal inhibitor, GANT61, increased the radiosensitivity in the organoids. These findings revealed that PC organoids using urine might become a useful tool for investigating the mechanisms of the pathogenesis and treatment of PC in dogs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.